Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark

BMC Public Health

Helle Kiellberg Larsen²  Kristian Kofoed²  Tine Rikke Jørgensen³  Jens Olsen¹ 

[1] Centre for Applied Health Services Research and Technology Assessment (CAST), University of Southern Denmark, J. B. Winslows Vej 9B, 5000, Odense C, Denmark;Department of Dermato-Venereology, Copenhagen University Hospital, Bispebjerg, Denmark;Sanofi Pasteur MSD ApS, 2800 Kgs., Lyngby, Denmark

关键词: HPV;    Incidence;    Cost;    Cancer;    Anogenital;   

Others  :  1162726
DOI  :  10.1186/1471-2458-12-1082

 received in 2012-05-22, accepted in 2012-12-13,  发布年份 2012

【 摘 要 】

Background

Besides being a causative agent for genital warts and cervical cancer, human papillomavirus (HPV) contributes to 40-85% of cases of anal, penile, vaginal and vulvar cancer and precancerous lesions. HPV types 16 & 18 in particular contribute to 74-93% of these cases. Overall the number of new cases of these four cancers may be relatively high implying notable health care cost to society. The aim of this study was to estimate the incidence and the health care sector costs of anal, penile, vaginal and vulvar cancer.

Methods

New anogenital cancer patients were identified from the Danish National Cancer Register using ICD-10 diagnosis codes. Resource use in the health care sector was estimated for the year prior to diagnosis, and for the first, second and third years after diagnosis. Hospital resource use was defined in terms of registered hospital contacts, using DRG (Diagnosis Related Groups) and DAGS (Danish Outpatient Groups System) charges as cost estimates for inpatient and outpatient contacts, respectively. Health care consumption by cancer patients diagnosed in 2004–2007 was compared with that by an age- and sex-matched cohort without cancer. Hospital costs attributable to four anogenital cancers were estimated using regression analysis.

Results

The annual incidence of anal cancer in Denmark is 1.9 per 100,000 persons. The corresponding incidence rates for penile, vaginal and vulvar cancer are 1.7, 0.9 and 3.6 per 100,000 males/females, respectively. The total number of new cases of these four cancers in Denmark is about 270 per year. In comparison, the total number of new cases cervical cancer is around 390 per year. The total cost of anogenital cancer to the hospital sector was estimated to be 7.6 million Euros per year. Costs associated with anal and vulvar cancer constituted the majority of the costs.

Conclusions

Anogenital cancer incurs considerable costs to the Danish hospital sector. It is expected that the current HPV vaccination program will markedly reduce this burden.

【 授权许可】

   
2012 Olsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3):S3-11-S3/25.
• [2]Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX: Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26(Suppl 10):K17-K28.
• [3]Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124:2375-2383.
• [4]Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL: Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med 2011, 53(Suppl 1):S12-S21.
• [5]Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S: Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62:870-878.
• [6]De VH, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
• [7]Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al.: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2:868-878.
• [8]Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365:1576-1585.
• [9]Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D: Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364:401-411.
• [10]Chaturvedi AK: Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010, 46:S20-S26.
• [11]National Board of Health [Sundhedsstyrelsen]: The Danish Cancer Register [Cancerregisteret 2009]. Copenhagen; 2009.
• [12]Bosch FX: Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin Pharmacother 2011, 12:2189-2204.
• [13]Douglas LR, Schiller JT: Reducing HPV-associated Cancer Globally. Cancer Prev Res 2012, 5:18-23.
• [14]Ministry of Health and Prevention, National Board of Health [Ministeriet for Sundhed og Forebyggelse, Sundhedsstyrelsen]: Charges 2008 - Instructions [Takstsystem 2008 - Vejledning]. Copenhagen; 2008.
• [15]Glick HA, Doshi JA, Sonnad SS, Polsky D: Analyzing cost. In Economic Evaluation in Clinical Trials. Oxford: Oxford University Press; 2007.
• [16]Lipscomb J, Ancukiewicz M, Parmigiani G, Hasselblad V, Samsa G, Matchar DB: Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making 1998, 18:S39-S56.
• [17]Blough DK, Madden CW, Hornbrook MC: Modeling risk using generalized linear models. J Health Econ 1999, 18:153-171.
• [18]Olsen J, Jepsen MR: Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010, 26:183-191.
• [19]Borget I, Abramowitz L, Mathevet P: Economic burden of HPV-related cancers in France. Vaccine 2011, 29:5245-5249.
• [20]Abramowitz L, Remy V, Vainchtock A: Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique 2010, 58:331-338.
• [21]Hu D, Goldie S: The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500-507.
• [22]Piana A, Sotgiu G, Castiglia P, Pischedda S, Cocuzza C, Capobianco G, et al.: Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, Italy. BMC Public Health 2011, 11:785. BioMed Central Full Text
• [23]Rousseau MC, Villa LL, Costa MC, Abrahamowicz M, Rohan TE, Franco E: Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis 2003, 30:581-587.